Literature DB >> 11375336

Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity.

A Basu1, R Basu, P Shah, A Vella, C M Johnson, M Jensen, K S Nair, W F Schwenk, R A Rizza.   

Abstract

We have previously reported that splanchnic glucose uptake, hepatic glycogen synthesis, and hepatic glucokinase activity are decreased in people with type 2 diabetes during intravenous glucose infusion. To determine whether these defects are also present during more physiological enteral glucose administration, we studied 11 diabetic and 14 nondiabetic volunteers using a combined organ catheterization-tracer infusion technique. Glucose was infused into the duodenum at a rate of 22 micromol. kg(-1). min(-1) while supplemental glucose was given intravenously to clamp glucose at approximately 10 mmol/l in both groups. Endogenous hormone secretion was inhibited with somatostatin, and insulin was infused to maintain plasma concentrations at approximately 300 pmol/l (i.e., twofold higher than our previous experiments). Total body glucose disappearance, splanchnic, and leg glucose extractions were markedly lower (P < 0.01) in the diabetic subjects than in the nondiabetic subjects. UDP-glucose flux, a measure of glycogen synthesis, was approximately 35% lower (P < 0.02) in the diabetic subjects than in the nondiabetic subjects. This was entirely accounted for by a decrease (P < 0.01) in the contribution of extracellular glucose because the contribution of the indirect pathway to hepatic glycogen synthesis was similar between groups. Neither endogenous and splanchnic glucose productions nor rates of appearance of the intraduodenally infused glucose in the portal vein differed between groups. In summary, both muscle and splanchnic glucose uptake are impaired in type 2 diabetes during enteral glucose administration. The defect in splanchnic glucose uptake appears to be due to decreased uptake of extracellular glucose, implying decreased glucokinase activity. Thus, abnormal hepatic and muscle (but not gut) glucose metabolism are likely to contribute to postprandial hyperglycemia in people with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375336     DOI: 10.2337/diabetes.50.6.1351

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  50 in total

1.  Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver.

Authors:  P Iozzo; R Lautamaki; F Geisler; K A Virtanen; V Oikonen; M Haaparanta; H Yki-Jarvinen; E Ferrannini; J Knuuti; P Nuutila
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 2.  Alterations of glucose metabolism in type 2 diabetes mellitus. An overview.

Authors:  Riccardo C Bonadonna
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  Insulin:Carbohydrate Ratio--Part of the Story.

Authors:  Ananda Basu; Rita Basu
Journal:  Diabetes Technol Ther       Date:  2015-12       Impact factor: 6.118

4.  Inhibiting gluconeogenesis prevents fatty acid-induced increases in endogenous glucose production.

Authors:  Sylvia Kehlenbrink; Julia Tonelli; Sudha Koppaka; Visvanathan Chandramouli; Meredith Hawkins; Preeti Kishore
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-05       Impact factor: 4.310

5.  Effects of type 2 diabetes and insulin on whole-body, splanchnic, and leg protein metabolism.

Authors:  Kevin R Short; Brian A Irving; Ananda Basu; C Michael Johnson; K Sreekumaran Nair; Rita Basu
Journal:  J Clin Endocrinol Metab       Date:  2012-10-02       Impact factor: 5.958

6.  GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization.

Authors:  Ko Kotani; Odile D Peroni; Yasuhiko Minokoshi; Olivier Boss; Barbara B Kahn
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

7.  Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.

Authors:  D J Baker; A M Atkinson; G P Wilkinson; G J Coope; A D Charles; B Leighton
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients.

Authors:  Daohua Shi; Tiancheng Xie; Jie Deng; Peiguang Niu; Weizhen Wu
Journal:  Eur J Clin Pharmacol       Date:  2018-03-15       Impact factor: 2.953

9.  Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs.

Authors:  Mary Courtney Moore; Kazuhiro Kimura; Haruki Shibata; Tsutomu Honjoh; Masayuki Saito; Carrie A Everett; Marta S Smith; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-03-08       Impact factor: 4.310

10.  Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments.

Authors:  Ling Hinshaw; Ashwini Mallad; Chiara Dalla Man; Rita Basu; Claudio Cobelli; Rickey E Carter; Yogish C Kudva; Ananda Basu
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-07       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.